Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 21, 2026.

Association of Chorioamnionitis With Bronchopulmonary Dysplasia Among Preterm Infants

Eduardo Villamor-Martinez, María Álvarez-Fuente, Amro M. T. Ghazi and 4 more

JAMA Network Open · 2019 · Meta-analysis

doi:10.1001/jamanetworkopen.2019.14611

Abstract

Question. Is chorioamnionitis a risk factor for developing bronchopulmonary dysplasia in preterm infants?

Findings. This systematic review, meta-analysis, and metaregression found that chorioamnionitis was associated with an increased risk of bronchopulmonary dysplasia in preterm infants but also found significant differences in baseline characteristics between infants with and infants without chorioamnionitis. A multivariate metaregression model combining the difference in gestational age and the odds of respiratory distress syndrome was associated with 64% of the variance in the association between chorioamnionitis and bronchopulmonary dysplasia.

Meaning. Exposure to chorioamnionitis is associated with a higher risk of developing bronchopulmonary dysplasia in preterm infants, but this association may be modulated by gestational age and risk of respiratory distress syndrome.

Importance. Bronchopulmonary dysplasia (BPD), a chronic lung disease of prematurity, remains one of the major and most common complications of very preterm birth. Insight into factors associated with the pathogenesis of BPD is key to improving its prevention and treatment.

Objective. To perform a systematic review, meta-analysis, and metaregression of clinical studies exploring the association between chorioamnionitis (CA) and BPD in preterm infants.

Data Sources. PubMed and Embase were searched without language restriction (last search, October 1, 2018). Key search terms included bronchopulmonary dysplasia, chorioamnionitis, and risk factors.

Study Selection. Included studies were peer-reviewed studies examining preterm (<37 weeks’ gestation) or very low-birth-weight (<1500 g) infants and reporting primary data that could be used to measure the association between exposure to CA and the development of BPD.

Data Extraction and Synthesis. The Meta-analysis of Observational Studies in Epidemiology (MOOSE) guideline was followed. Data were independently extracted by 2 researchers. A random-effects model was used to calculate odds ratios (ORs) and 95% CIs. Heterogeneity in effect size across studies was studied using multivariate, random-effects metaregression analysis.

Main Outcomes and Measures. The primary outcome was BPD, defined as supplemental oxygen requirement on postnatal day 28 (BPD28) or at the postmenstrual age of 36 weeks (BPD36). Covariates considered as potential confounders included differences between CA-exposed and CA-unexposed infants in gestational age, rates of respiratory distress syndrome (RDS), exposure to antenatal corticosteroids, and rates of early- and late-onset sepsis.

Results. A total of 3170 potentially relevant studies were found, of which 158 met the inclusion criteria (244 096 preterm infants, 20 971 CA cases, and 24 335 BPD cases). Meta-analysis showed that CA exposure was significantly associated with BPD28 (65 studies; OR, 2.32; 95% CI, 1.88-2.86; P <.001; heterogeneity: I2 = 84%; P <.001) and BPD36 (108 studies; OR, 1.29; 95% CI, 1.17-1.42; P <.001; heterogeneity: I2 = 63%; P <.001). The association between CA and BPD remained significant for both clinical and histologic CA. In addition, significant differences were found between CA-exposed and CA-unexposed infants in gestational age, birth weight, odds of being small for gestational age, exposure to antenatal corticosteroids, and early- and late-onset sepsis. Chorioamnionitis was not significantly associated with RDS (48 studies; OR, 1.10; 95% CI, 0.92-1.34; P =.24; heterogeneity: I2 = 90%; P <.001), but multivariate metaregression analysis with backward elimination revealed that a model combining the difference in gestational age and the odds of RDS was associated with 64% of the variance in the association between CA and BPD36 across studies.

Conclusions and Relevance. The results of this study confirm that among preterm infants, exposure to CA is associated with a higher risk of developing BPD, but this association may be modulated by gestational age and risk of RDS.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 21, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Bronchopulmonary dysplasia (BPD), a chronic lung disease of prematurity, remains one of the major and most common complications of very preterm birth.,,,,,, The degree of prematurity is the most important predisposing risk factor for BPD, but inflammatory and/or infectious events are suggested to play a key role in the initiation, progression, and severity of BPD.,,,,,,,, The pulmonary inflammatory response may have been initiated in utero, in the setting of chorioamnionitis (CA).,,,,,

Besides the aforementioned detrimental effects, clinical observations support the concept that fetal exposure to infection or inflammation may also be beneficial to the very preterm lung.,, Watterberg et al were the first to report that CA was associated with an increased risk for BPD but a reduced risk for respiratory distress syndrome (RDS). This observation led to the hypothesis that CA exposure accelerated functional lung maturation but increased the vulnerability of the preterm lung to postnatal injury.,, However, the data supporting this hypothesis are inconsistent, and subsequent studies during the past 20 years have found that CA was associated with increased, decreased, or no risk of either BPD or RDS.,,

The role of CA as a potential pathogenic factor for BPD has already been the subject of a systematic review and meta-analysis. Hartling et al included 59 studies (15 295 preterm infants). They found in unadjusted analyses that CA was significantly associated with BPD (odds ratio [OR], 1.89; 95% CI, 1.56-2.30). They found substantial statistical heterogeneity and evidence of publication bias. They also observed that infants exposed to CA had a significantly lower gestational age and birth weight than infants who were not exposed to CA. Moreover, studies adjusting for important confounders (including gestational age and/or birth weight) showed more conservative measures of association between CA and BPD. They concluded that “despite a large body of evidence, CA cannot be definitely considered a risk factor for BPD.”(pF8)

After the publication of the meta-analysis by Hartling et al, many more studies assessing the association between CA and BPD have been published. Some of these studies are of high methodological quality and included a large number of infants. Therefore, in the present study, we aimed to update and expand the meta-analysis of Hartling et al. In addition, we investigated not only the association between CA and BPD but also the association between CA and RDS and how these 2 associations correlate. We also analyzed the role of potential confounders or intermediate factors, such as gestational age, birth weight, the presence of fetal inflammatory response (ie, funisitis), exposure to antenatal corticosteroids, sepsis, or patent ductus arteriosus, in the association between CA and BPD.

Methods

We based the method for this systematic review, meta-analysis, and metaregression on earlier meta-analyses on the associations between CA and patent ductus arteriosus, CA and retinopathy of prematurity, and CA and intraventricular hemorrhage. The study was conducted according to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting guideline and the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. A protocol was developed prospectively that detailed the specific objectives, criteria for study selection, approach to assessing study quality, clinical outcomes, and statistical methods. The study is reported according to the PRISMA checklist.

Sources and Search Strategy

A comprehensive literature search was undertaken using the PubMed/MEDLINE and Embase databases from their inception to October 1, 2018. The search terms involved various combinations of the following key words: chorioamnionitis, intrauterine infection, intrauterine inflammation, antenatal infection, antenatal inflammation, bronchopulmonary dysplasia, chronic lung disease, risk factors, outcome, cohort, and case-control. No language limit was applied. Narrative reviews, systematic reviews, case reports, letters, editorials, and commentaries were excluded but were read to identify potential additional studies. Additional strategies to identify studies included a manual review of reference lists from key articles that fulfilled our eligibility criteria and other systematic reviews on CA, use of the “related articles” feature in PubMed, and use of the “cited by” tool in Web of Science and Google Scholar.

Study Selection

Studies were included if they examined preterm (gestational age <37 weeks) or very low-birth-weight (<1500 g) infants and reported primary data that could be used to measure the association between exposure to CA and the development of BPD. Therefore, we selected studies assessing the outcomes of infants exposed to CA when BPD was one of the reported outcomes and studies assessing the risk factors for BPD when CA was one of the reported risk factors. To identify relevant studies, 2 of us (A.M.T.G. and E.V.) independently screened the results of the searches and applied inclusion criteria using a structured form. Discrepancies were resolved through discussion or consultation with a third reviewer (P.D.).

Data Extraction

Two of us (A.M.T.G. and P.D.) extracted data from relevant studies using a predetermined data extraction form, and 3 of us (E.V.-M., M.A.-F., and E.V.) checked data extraction for accuracy and completeness. Discrepancies were resolved by consulting the primary report. Data extracted from each study included citation information, language of publication, location where research was conducted, time period of the study, study objectives, study design, definitions of CA and BPD, inclusion and exclusion criteria, patient characteristics, and results (including raw numbers, summary statistics, and adjusted analyses on CA and BPD when available). Studies that did not define CA were assumed to use a clinical definition. Bronchopulmonary dysplasia defined as supplemental oxygen requirement on postnatal day 28 was coded as BPD28. Bronchopulmonary dysplasia defined as oxygen requirement at the postmenstrual age (PMA) of 36 weeks (with or without physiological challenge of supplemental oxygen withdrawal) was coded as BPD36. Using these definition criteria, BPD28 was considered to include all severities of BPD, whereas BPD36 was considered to include a combination of moderate and severe BPD. Data on separate categories of BPD (mild, moderate, and severe) were collected when available.

Quality Assessment

Methodological quality was assessed using the Newcastle-Ottawa Scale for cohort or case-control studies. This scale uses a rating system (range, 0-9 points; higher scores indicate reduced bias) that scores 3 aspects of a study: selection (0-4 points), comparability (0-2 points), and exposure or outcome (0-3 points). Studies were evaluated as though the association between CA and BPD was the primary outcome. Two of us (E.V.-M. and E.V.) independently assessed the methodological quality of each study. Discrepancies were resolved through discussion.

Statistical Analysis

Studies were combined and analyzed using Comprehensive Meta-Analysis, version 3.0 software (Biostat Inc). For dichotomous outcomes, the OR with 95% CI was calculated from the data provided in the studies. Odds ratios adjusted for potential confounders were extracted from the studies reporting these data. For continuous outcomes, the mean difference with 95% CI was calculated. When studies reported continuous variables as median and range or interquartile range, we estimated the mean and SD using the method of Wan et al and the calculator they provided.

Owing to anticipated heterogeneity, summary statistics were calculated with a random-effects model. This model accounts for variability between studies as well as within studies. Subgroup analyses were conducted according to the mixed-effects model. In this model, a random-effects model is used to combine studies within each subgroup, and a fixed-effect model is used to combine subgroups and yield the overall effect. The study-to-study variance (τ2) is not assumed to be the same for all subgroups. This value is computed within subgroups and not pooled across subgroups. Statistical heterogeneity was assessed by use of the Cochran Q statistic and by use of the I2 statistic, which is derived from the Q statistic and describes the proportion of total variation that is due to heterogeneity beyond chance. We used the Egger regression test and funnel plots to assess publication bias.

To explore differences between studies that might be expected to influence the effect size, we performed random effects (method of moments) univariate and multivariate metaregression analyses. The potential sources of variability defined a priori were CA type (clinical or histologic), differences in gestational age and birth weight between infants with and infants without CA, use of antenatal corticosteroids, mode of delivery, rate of small-for-gestational-age infants, rate of premature rupture of membranes, rate of preeclampsia, rate of early-onset sepsis, rate of late-onset sepsis, rate of RDS, and mortality. Covariates were selected for further modeling if they significantly (P <.05) modified the association between CA and BPD. Subsequently, preselected covariates were included in a backward multiple metaregression analysis with P =.05 as a cutoff point for removal. P <.05 (P <.10 for heterogeneity) was considered statistically significant. All tests were 2-tailed.

Description of Studies

Of 3170 potentially relevant studies, 158 (5.0%),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, met the inclusion criteria. The PRISMA flow diagram of the search process is shown in Figure 1. The included studies evaluated 244 096 preterm infants and included 20 791 CA cases and 24 335 cases of BPD of any severity. The included studies and their characteristics are summarized in eTable 1 in the Supplement. Seventy-six studies,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, were designed from the perspective of CA; they examined the outcomes of preterm infants with or without CA, and BPD was one of these outcomes. Sixty-seven studies,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, were designed from the perspective of BPD; they studied risk factors for BPD, and CA was one of these risk factors. Sixteen studies,,,,,,,,,,,,,,, were designed to primarily examine the association between CA and BPD. Forty-eight included studies examined the association between CA and RDS.

Forty-two studies defined CA clinically, and 97 studies defined CA histologically. Six studies provided BPD outcomes for infants with histologic and clinical CA separately.,,,,, One study required infants to have both histologic and clinical CA to be considered exposed to CA. Nine studies defined CA using a microbiological definition.,,,,,,,, Finally, 16 studies,,,,,,,,,,,,,,, did not define CA and, for the purposes of analysis, were considered to evaluate clinical CA.

Most studies included infants with a gestational age less than 32 weeks or a birth weight less than 1500 g, as described in eTable 1 in the Supplement. Eighty-one studies included infants who were 32 weeks’ gestational age or more preterm, 27 studies included infants who were at most 32 to 34 weeks’ gestational age, and 10 studies included infants who were less than 34 to 37 weeks’ gestational age. Nine studies included infants who had a birth weight of less than 1000 g, 49 studies included infants who had a birth weight of 1500 g or less, and 2 studies included infants who had a birth weight of 2000 g or less. Finally, 4 studies used inclusion criteria (clarified per study in eTable 1 in the Supplement) other than gestational age or birth weight.

Sixty-five studies provided data on BPD28, and 108 studies provided data on BPD36. Fifteen studies provided data on the incidence of mild BPD, 7 studies provided data on the incidence of moderate BPD, and 8 studies provided data on the incidence of severe BPD.

Analysis Based on Unadjusted Data

Meta-analysis found a positive association between exposure to CA and BPD28 (65 studies; OR, 2.32; 95% CI, 1.88-2.86; P <.001; heterogeneity: I2 = 84%; P <.001) (Figure 2A). When subdividing by definition of CA, we found that the association with BPD28 remained significant for histologic CA (OR, 2.58; 95% CI, 1.99-3.34), clinical CA (OR 1.77, 95% CI, 1.21-2.61), and microbiological CA (OR, 2.99; 95% CI, 1.03-8.68) (Figure 2A; eFigure 1 in the Supplement). We also found a significant positive association between CA and BPD36 (108 studies; OR, 1.29; 95% CI, 1.17-1.42; P <.001; heterogeneity: I2 = 63%; P <.001) (Figure 2B). This association was also significant when pooling only studies of histologic CA (OR, 1.33; 95% CI, 1.18-1.51) (Figure 2B; eFigure 2 in the Supplement) and clinical CA (OR, 1.24; 95% CI, 1.03-1.49) (Figure 2B; eFigure 3 in the Supplement).

When further stratified by grade of BPD, meta-analysis did not find a significant association between CA and mild BPD (15 studies; Figure 2C; eFigure 4 in the Supplement), moderate BPD (7 studies; Figure 2D; eFigure 5 in the Supplement), or severe BPD (8 studies; Figure 2E; eFigure 6 in the Supplement). Twenty-three of the 158 included studies also reported on funisitis and risk of BPD. Meta-analysis did not find a difference between infants exposed to CA with funisitis and infants exposed to CA without funisitis in the risk of BPD28 (OR, 1.26; 95% CI, 0.61-2.59) or the risk of BPD36 (OR, 1.19; 95% CI, 0.77-1.83) (eFigure 7 in the Supplement).

Analysis of Adjusted Data

To examine confounding factors, we pooled studies that provided adjusted data on the association between CA and BPD. Eleven studies reported adjusted data on BPD28. Meta-analysis of these adjusted data showed a significant association between CA and BPD28 (OR, 1.68; 95% CI, 1.28-2.21) (eFigure 8 in the Supplement). When the unadjusted data on BPD28 from the 11 studies were pooled, the OR increased to 2.17 (95% CI, 1.71-2.76). However, metaregression did not find this increase in effect size to be statistically significant (P =.17).

Twenty-one studies reported adjusted data on BPD36. Meta-analysis of these adjusted data showed a significant association between CA and BPD36 (OR, 1.25; 95% CI, 1.01-1.54) (eFigure 9 in the Supplement). When the unadjusted data on BPD36 of the 21 studies were pooled, the OR increased to 1.65 (95% CI, 1.37-2.00). Metaregression did not find this increase in effect size to be statistically significant (P =.05).

Analysis of Covariates and Metaregression

We performed additional meta-analyses to explore the possible differences in baseline characteristics between the groups exposed or nonexposed to CA. As summarized in the Table, infants exposed to CA showed a significantly lower gestational age (difference in means, –1.20 weeks; 95% CI, –1.48 to –0.92 weeks) and birth weight (difference in means, –48 g; 95% CI, –66 to –30 g) and significantly lower rates of birth by cesarean delivery (OR, 0.35; 95% CI, 0.28-0.43), small for gestational age (OR, 0.34; 95% CI, 0.26-0.44), and preeclampsia (OR, 0.16; 95% CI, 0.11-0.23). Moreover, infants exposed to CA showed significantly higher rates of exposure to antenatal corticosteroids (OR, 1.39; 95% CI, 0.98-1.97), premature rupture of membranes (OR, 3.66; 95% CI, 3.02-4.44), early-onset sepsis (OR, 3.18; 95% CI, 2.41-4.19), late-onset sepsis (OR, 1.32; 95% CI, 1.10-1.58), and mortality (OR, 1.48; 95% CI, 1.28-1.71). In contrast, meta-analysis did not demonstrate a significant association between CA and all RDS (OR, 1.10; 95% CI, 0.92-1.34; P =.24; heterogeneity: I2 = 90%; P <.001) (Figure 3; eFigure 10 in the Supplement) or severe RDS (defined by the necessity of surfactant and/or mechanical ventilation) (Figure 3; eFigure 11 in the Supplement).

Relevant covariates were preselected using univariate metaregression analyses. Results of all univariate analyses are presented in eTable 2 in the Supplement. For BPD28, we found that mean difference in gestational age significantly explained heterogeneity in effect size across studies (eTable 2 in the Supplement). For BPD36, we found that mean difference in gestational age (eFigure 12 and eTable 2 in the Supplement), mean difference in birth weight (eTable 2 in the Supplement), and RDS risk (eFigure 13 and eTable 2 in the Supplement) significantly explained heterogeneity in effect size across studies; these variables were therefore considered for further modeling. Backward multiple metaregression analysis, including all studies on BPD36 with complete data for these 3 covariates (gestational age, birth weight, and RDS; k = 25), revealed that heterogeneity in effect size across studies was significantly explained by the mean difference in gestational age (coefficient, –0.23; 95% CI, −0.40 to −0.06; P =.008) and risk of RDS (coefficient, 0.31; 95% CI, 0.09-0.54; P =.007). We retested this model, including all studies with complete data on mean difference in gestational age and risk of RDS (k = 27) (Figure 4). This final model had a total explained variance of 64% (R2 equivalent). The variance did not seem to be inflated owing to multicollinearity (variance inflation factor = 1.08). Each week that infants with CA are born earlier than control infants resulted in an increase in BPD36 log OR of 0.23 (the equivalent of going from an OR of 1.00 to an OR of 1.70). Each point increase in the RDS log OR resulted in an increase in the BPD36 log OR of 0.31 (the equivalent of going from an OR of 1.00 to an OR of 2.04).

To further assess gestational age as a confounding factor, we performed a meta-analysis of studies in which the mean difference in gestational age was not significant (P >.05). As shown in eFigure 14 in the Supplement, we observed no differences in BPD28 risk in studies with similar gestational age (6 studies). On the other hand, when a significant difference in gestational age was observed (P <.05), CA was significantly associated with BPD28 (20 studies; OR, 2.00; 95% CI, 1.49-2.69) (eFigure 14 in the Supplement). We found similar results for BPD36. Meta-analysis of studies in which the mean difference in gestational age was not significant did not find an association between CA and BPD36 (15 studies; eFigure 15 in the Supplement), whereas meta-analysis of studies in which the difference in gestational age was significant found a significant association between CA and BPD36 risk (32 studies; OR, 1.43; 95% CI, 1.23-1.67).

Quality Assessment

The quality of each study according to the Newcastle-Ottawa Scale is summarized in eTable 3 in the Supplement. Studies received a quality score of 6 points (2 studies), 7 points (21 studies), 8 points (112 studies), or 9 points (23 studies), out of a possible 9 points. Studies were downgraded in quality most frequently for not adjusting the risk of BPD for confounders (133 studies), for not defining CA clearly (16 studies), and for not defining BPD precisely (3 studies).

Publication Bias

Neither visual inspection of funnel plots (eFigure 16 in the Supplement) nor the Egger test suggested publication or selection bias. There was an insufficient number of studies with other BPD definitions (ie, mild, moderate, or severe) to evaluate publication bias.

Discussion

The present study is a substantial update to the systematic review of Hartling et al, including a larger number of studies (158 vs 59), a much larger number of infants (244 096 vs 15 295), and a wider range of analysis of covariates. Our study confirms the results of Hartling et al and adds new information on the role of funisitis and RDS, which have not been previously systematically reviewed, to our knowledge. Chorioamnionitis was a significant risk factor for BPD28 (all BPD) and for BPD36 (moderate and severe BPD), but a significant association with severe BPD was not demonstrated. Exposure to funisitis was not significantly associated with a higher risk of BPD compared with exposure to CA in the absence of funisitis. Meta-analysis did not demonstrate a significant association between CA and RDS. As in earlier meta-analyses of CA and morbidities,,, we found significant differences between CA-exposed and CA-unexposed infants in gestational age, birth weight, odds of being small for gestational age, exposure to antenatal corticosteroids, early- and late-onset sepsis, and patent ductus arteriosus. Multivariate metaregression analysis revealed that a model combining the difference in gestational age and the odds of RDS explained 64% of the variance in the association between CA and BPD36 across studies. In conclusion, our results confirm the positive association between CA and BPD in preterm infants, but the pathogenic effect of CA on BPD may be modulated by the effect of CA on gestational age and risk of RDS.

As discussed elsewhere, one important limitation inherent to any meta-analysis of BPD is the heterogeneity of the definition of the condition.,, The first clinical definition for BPD was adopted as infants requiring supplemental oxygen on postnatal day 28., In 1988, the definition was refined to oxygen use at 36 weeks of PMA, and 12 years later, a categorization of BPD as mild, moderate, or severe was proposed. Mild BPD included infants who received oxygen or respiratory support at the postnatal age of 28 days but who were breathing room air at 36 weeks PMA. When infants required supplemental oxygen at 36 weeks PMA, BPD was classified as moderate (need for <30% oxygen) or severe (need for ≥30% oxygen and/or positive airway pressure). A further refinement in the definition included a physiological challenge of supplemental oxygen withdrawal to test for oxygen need at 36 weeks PMA. Most of the studies included in our meta-analysis defined BPD using the 36 weeks of PMA criteria (BPD36). Therefore, they provided data on combined moderate and severe BPD. This combination fails to differentiate the infants with more severe BPD, who remain dependent on mechanical ventilation and more often have severe complications, including pulmonary hypertension, poor growth, and neurodevelopmental problems. Only 7 studies provided separate data on severe BPD. Meta-analysis could not demonstrate a significant association between CA and severe BPD, but the small number of studies is the main limitation of this subanalysis.

Another main difficulty when assessing CA as a risk factor for neonatal adverse outcomes is the absence of a “healthy” control group. Possible causes of very preterm birth (ie, gestational age <32 weeks) can be divided into 2 main categories: infection and/or inflammation and dysfunctional placentation. Chorioamnionitis is associated with infection and/or inflammation, and we and others have previously found that infants exposed to CA differ substantially from nonexposed infants in relevant clinical characteristics and outcomes.,, We replicated these findings in the present study and found that CA-exposed infants were born earlier (1.2 weeks) and weighed less (48 g) than infants without CA. In addition, they were more frequently exposed to antenatal corticosteroids, they were less frequently small for gestational age, and they had higher rates of early- and late-onset sepsis, as well as a higher mortality rate. We performed metaregression to analyze how these differences between the CA-exposed and the nonexposed infants affected the association between CA and BPD. Univariate metaregression showed that differences in gestational age and birth weight, as well as rate of RDS, significantly modified the CA-associated risk of BPD36. As already mentioned, multivariate regression found that 64% of variance in CA-associated BPD risk was explained by the differences in gestational age and rate of RDS.

The so-called Waterberg hypothesis or early-protection, late-damage effect suggests that CA may be associated with a reduction in RDS but an increase in BPD.,, To test this hypothesis, we also analyzed the association between CA and RDS in the included studies. In contrast to BPD, meta-analysis of unadjusted data could not demonstrate a significant association between CA and the development of RDS. Prematurity is the most important risk factor for RDS. The CA-exposed infants were born 1.2 weeks earlier but did not show a higher rate of RDS. This finding may suggest some degree of protection against RDS, compatible with the Waterberg hypothesis. In contrast, metaregression showed a significant positive association between the effect size of the CA-RDS association and the effect size of the CA-BPD association (eFigure 12 in the Supplement). In other words, the studies showing a higher risk of RDS in the CA group also showed a higher risk of BPD. Nevertheless, our results should be interpreted with caution because the criteria for the definition of RDS varied substantially among the different studies. As pointed out by Jobe and Kallapur, although RDS is the diagnosis assigned to most preterm infants, it is unlikely that they have only 1 lung disease at birth. We therefore restrained the analysis to the studies defining a more severe form of RDS (ie, RDS requiring surfactant and/or mechanical ventilation), which, however, did not modify the lack of association between CA and RDS.

It remains unclear whether the most severe grades of CA with a fetal inflammatory response further increase the risk for developing BPD and/or RDS. Funisitis is considered the histologic counterpart of the fetal inflammatory response syndrome., Been et al showed that the presence of funisitis categorized infants at risk for severe RDS who were less responsive to surfactant treatment. In contrast, infants exposed to CA without funisitis had less severe RDS than did infants without the CA exposure. Therefore, exposure to CA and/or funisitis may be more strongly associated with the severity than with the incidence of respiratory complications. Our meta-analysis did not demonstrate that the presence of funisitis significantly increased the risk of BPD or RDS compared with CA in the absence of funisitis (eFigure 7 in the Supplement). However, our meta-analysis is limited by the small number of studies providing data on funisitis. In addition, infants with funisitis also presented with differences in basal characteristics (including lower gestational age) compared with infants with CA without funisitis.,,

Limitations and Strengths

Hartling et al noted 2 problems that made the interpretation of their results difficult: significant publication bias and substantial statistical heterogeneity. Our larger study showed a similarly high degree of heterogeneity, but we did not find statistical evidence of publication bias. Egger regression can test only for data trends that may be caused by selective reporting, publication, or inclusion. Even highly significant data trends do not necessarily mean that the results of the primary analysis are biased. In addition, the Egger regression test has a high type I error rate and may generate false-positives when dealing with many studies and a high degree of heterogeneity.

Some additional limitations of our systematic review and meta-analysis deserve consideration. First, the published literature showed great heterogeneity in the definition of CA and in the assessment of confounders. In particular, criteria for the use of the term clinical CA are highly variable, and recent recommendations propose restricting the term chorioamnionitis to pathologic diagnosis. In addition, the term funisitis was not included in our search strategy. Second, only a limited number of studies evaluated the association between CA and BPD as their main objective. Similarly, adjusted data were available only from a subset of all studies included in the meta-analysis. In addition, we had to rely on the adjusted analyses as presented in the published reports and the variables for which they adjusted, which were not consistent across studies. Third, metaregression uses summary data at the study level, which means that we cannot comment on data of individual infants within a study and that there is a risk of ecological bias. The main strengths of the present study are the large number of studies included and the use of rigorous methods, including duplicate screening, inclusion, and data extraction to reduce bias; meta-analysis of baseline and secondary characteristics; and the use of metaregression to control for potential confounders.

Conclusions

Overall, the results of this study confirm that, among preterm infants, exposure to CA is associated with a higher risk of developing BPD, but this association may be modulated by gestational age and risk of RDS. Bronchopulmonary dysplasia remains a persistent problem in part because advances in neonatal care have improved the survival of the youngest and smallest infants, who are more prone to develop BPD. Our data show that CA is frequently the cause of prematurity among these youngest and smallest infants. This higher degree of prematurity may alter the association between CA and BPD. In addition, CA may initiate the pathogenic sequence leading to BPD but also may alter the rate of exposure to other anti-inflammatory or proinflammatory stimuli, such as antenatal corticosteroids, RDS, patent ductus arteriosus, mechanical ventilation, oxygen, and sepsis. Nevertheless, CA, RDS, and BPD are imprecise diagnoses and have been partially changed over time, making the analysis of their associations and correlations difficult.

References 199

  1. 1.

    Farstad T, Bratlid D, Medbø S, Markestad T; Norwegian Extreme Prematurity Study Group Bronchopulmonary dysplasia—prevalence, severity and predictive factors in a national cohort of extremely premature infants. Acta Paediatr. 2011;100(1):-

    Not in our library10.1111/j.1651-2227.2010.01959.x

  2. 2.

    Jobe AH, Bancalari E Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163(7):1723-1729

    Not in our library10.1164/ajrccm.163.7.2011060

  3. 3.

    Kramer BW Antenatal inflammation and lung injury: prenatal origin of neonatal disease. J Perinatol. 2008;28(suppl 1):S21-S27

    Not in our library10.1038/jp.2008.46

  4. 4.

    Kramer BW, Kallapur S, Newnham J, Jobe AH, eds. Prenatal Inflammation and Lung Development: Seminars in Fetal and Neonatal Medicine. Amsterdam, the Netherlands: Elsevier; 2009

    Not in our library10.1016/j.siny.2008.08.011

  5. 5.

    Higgins RD, Jobe AH, Koso-Thomas M, Bronchopulmonary dysplasia: executive summary of a workshop. J Pediatr. 2018;197:300-308

    Not in our library10.1016/j.jpeds.2018.01.043

  6. 6.

    Abman SH, Collaco JM, Shepherd EG,; Bronchopulmonary Dysplasia Collaborative Interdisciplinary care of children with severe bronchopulmonary dysplasia. J Pediatr. 2017;181:12-28.e1

    Not in our library10.1016/j.jpeds.2016.10.082

  7. 7.

    Stoll BJ, Hansen NI, Bell EF,; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. JAMA. 2015;314(10):1039-1051

    Not in our library10.1001/jama.2015.10244

  8. 8.

    Shahzad T, Radajewski S, Chao C-M, Bellusci S, Ehrhardt H Pathogenesis of bronchopulmonary dysplasia: when inflammation meets organ development. Mol Cell Pediatr. 2016;3(1):23

    Not in our library10.1186/s40348-016-0051-9

  9. 9.

    Speer CP Chorioamnionitis, postnatal factors and proinflammatory response in the pathogenetic sequence of bronchopulmonary dysplasia. Neonatology. 2009;95(4):353-361

    Not in our library10.1159/000209301

  10. 10.

    Hartling L, Liang Y, Lacaze-Masmonteil T Chorioamnionitis as a risk factor for bronchopulmonary dysplasia: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2012;97(1):F8-F17

    Not in our library10.1136/adc.2010.210187

  11. 11.

    Thomas W, Speer CP Chorioamnionitis is essential in the evolution of bronchopulmonary dysplasia—the case in favour. Paediatr Respir Rev. 2014;15(1):49-52.

    Not in our library10.1016/j.prrv.2013.09.004

  12. 12.

    Lacaze-Masmonteil T That chorioamnionitis is a risk factor for bronchopulmonary dysplasia—the case against. Paediatr Respir Rev. 2014;15(1):53-55.

    Not in our library10.1016/j.prrv.2013.09.005

  13. 13.

    Van Marter LJ, Dammann O, Allred EN,; Developmental Epidemiology Network Investigators Chorioamnionitis, mechanical ventilation, and postnatal sepsis as modulators of chronic lung disease in preterm infants. J Pediatr. 2002;140(2):171-176

    Not in our library10.1067/mpd.2002.121381

  14. 14.

    Been JV, Zimmermann LJ Histological chorioamnionitis and respiratory outcome in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2009;94(3):F218-F225

    Not in our library10.1136/adc.2008.150458

  15. 15.

    Watterberg KL, Demers LM, Scott SM, Murphy S Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics. 1996;97(2):210-215.

    Not in our library

  16. 16.

    Viscardi RM Perinatal inflammation and lung injury. Semin Fetal Neonatal Med. 2012;17(1):30-35

    Not in our library10.1016/j.siny.2011.08.002

  17. 17.

    Behbodi E, Villamor-Martínez E, Degraeuwe PL, Villamor E Chorioamnionitis appears not to be a risk factor for patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. Sci Rep. 2016;6:37967

    Not in our library10.1038/srep37967

  18. 18.

    Villamor-Martinez E, Cavallaro G, Raffaeli G, Chorioamnionitis as a risk factor for retinopathy of prematurity: an updated systematic review and meta-analysis. PLoS One. 2018;13(10):e0205838

    Not in our library10.1371/journal.pone.0205838

  19. 19.
    Chorioamnionitis Is a Risk Factor for Intraventricular Hemorrhage in Preterm Infants: A Systematic Review and Meta-Analysis · 2018
    Not checked
  20. 20.

    Stroup DF, Berlin JA, Morton SC, Meta-analysis of observational studies in epidemiology: a proposal for reporting: Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-2012

    Not in our library10.1001/jama.283.15.2008

  21. 21.
    Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement · 2009
    No notice
  22. 22.

    Wells GA, Shea B, O’Connell D, The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. Accessed December 1, 2016.

    Not in our library

  23. 23.
    Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range · 2014
    No notice
  24. 24.
    Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range · 2014
    No notice
  25. 25.

    Borenstein M, Hedges LV, Higgins J, Rothstein HR Subgroup analyses In: Introduction to Meta-analysis. Chichester, UK: John Wiley & Sons Ltd; 2009:149-186

    Not in our library10.1002/9780470743386.ch19

  26. 26.

    Borenstein M, Hedges LV, Higgins J, Rothstein HR Identifying and quantifying heterogeneity Introduction to Meta-analysis. Chichester, UK: John Wiley & Sons Ltd; 2009:107-126

    Not in our library10.1002/9780470743386.ch16

  27. 27.

    Borenstein M, Hedges LV, Higgins J, Rothstein HR Meta-regression Introduction to Meta-analysis. Chichester, UK: John Wiley & Sons Ltd; 2009:187-203

    Not in our library10.1002/9780470743386.ch20

  28. 28.

    Abele-Horn M, Genzel-Boroviczény O, Uhlig T, Zimmermann A, Peters J, Scholz M Ureaplasma urealyticum colonization and bronchopulmonary dysplasia: a comparative prospective multicentre study. Eur J Pediatr. 1998;157(12):1004-1011

    Not in our library10.1007/s004310050987

  29. 29.

    Abele-Horn M, Peters J, Genzel-Boroviczény O, Wolff C, Zimmermann A, Gottschling W Vaginal ureaplasma urealyticum colonization: influence on pregnancy outcome and neonatal morbidity. Infection. 1997;25(5):286-291

    Not in our library10.1007/bf01720398

  30. 30.

    Ahn HM, Park EA, Cho SJ, Kim YJ, Park HS The association of histological chorioamnionitis and antenatal steroids on neonatal outcome in preterm infants born at less than thirty-four weeks’ gestation. Neonatology. 2012;102(4):259-264

    Not in our library10.1159/000339577

  31. 31.

    Arayici S, Kadioglu Simsek G, Oncel MY, The effect of histological chorioamnionitis on the short-term outcome of preterm infants ≤32 weeks: a single-center study. J Matern Fetal Neonatal Med. 2014;27(11):1129-1133

    Not in our library10.3109/14767058.2013.850668

  32. 32.

    Barrera-Reyes RH, Ruiz-Macías H, Segura-Cervantes E Neurodevelopment at one year of age [corrected] in preterm newborns with history of maternal chorioamnionitis [in Spanish]. Ginecol Obstet Mex. 2011;79(1):31-37.

    Not in our library

  33. 33.

    Baud O, Zupan V, Lacaze-Masmonteil T, The relationships between antenatal management, the cause of delivery and neonatal outcome in a large cohort of very preterm singleton infants. BJOG. 2000;107(7):877-884

    Not in our library10.1111/j.1471-0528.2000.tb11086.x

  34. 34.

    Been JV, Rours IG, Kornelisse RF, Jonkers F, de Krijger RR, Zimmermann LJ Chorioamnionitis alters the response to surfactant in preterm infants. J Pediatr. 2010;156(1):10-15.e1

    Not in our library10.1016/j.jpeds.2009.07.044

  35. 35.

    Alfiero Bordigato M, Piva D, Di Gangi IM, Giordano G, Chiandetti L, Filippone M Asymmetric dimethylarginine in ELBW newborns exposed to chorioamnionitis. Early Hum Dev. 2011;87(2):143-145

    Not in our library10.1016/j.earlhumdev.2010.11.004

  36. 36.

    Botet F, Figueras J, Carbonell-Estrany X, Narbona E The impact of clinical maternal chorioamnionitis on neurological and psychological sequelae in very-low-birth weight infants: a case-control study. J Perinat Med. 2011;39(2):203-208

    Not in our library10.1515/jpm.2011.005

  37. 37.

    Bry KJ, Jacobsson B, Nilsson S, Bry K Gastric fluid cytokines are associated with chorioamnionitis and white blood cell counts in preterm infants. Acta Paediatr. 2015;104(6):575-580

    Not in our library10.1111/apa.12947

  38. 38.

    Chisholm KM, Heerema-McKenney A, Tian L, Correlation of preterm infant illness severity with placental histology. Placenta. 2016;39:61-69

    Not in our library10.1016/j.placenta.2016.01.012

  39. 39.

    Choi CW, Kim BI, Joung KE, Decreased expression of transforming growth factor-beta1 in bronchoalveolar lavage cells of preterm infants with maternal chorioamnionitis. J Korean Med Sci. 2008;23(4):609-615

    Not in our library10.3346/jkms.2008.23.4.609

  40. 40.

    De Felice C, Toti P, Parrini S, Histologic chorioamnionitis and severity of illness in very low birth weight newborns. Pediatr Crit Care Med. 2005;6(3):298-302

    Not in our library10.1097/01.pcc.0000160658.35437.65

  41. 41.

    Dempsey E, Chen M-F, Kokottis T, Vallerand D, Usher R Outcome of neonates less than 30 weeks gestation with histologic chorioamnionitis. Am J Perinatol. 2005;22(3):155-159

    Not in our library10.1055/s-2005-865020

  42. 42.

    Dessardo NS, Dessardo S, Mustać E, Banac S, Petrović O, Peter B Chronic lung disease of prematurity and early childhood wheezing: is foetal inflammatory response syndrome to blame? Early Hum Dev. 2014;90(9):493-499

    Not in our library10.1016/j.earlhumdev.2014.07.002

  43. 43.

    Dexter SC, Malee MP, Pinar H, Hogan JW, Carpenter MW, Vohr BR Influence of chorioamnionitis on developmental outcome in very low birth weight infants. Obstet Gynecol. 1999;94(2):267-273.

    Not in our library10.1016/s0029-7844(99)00319-1

  44. 44.

    Dexter SC, Pinar H, Malee MP, Hogan J, Carpenter MW, Vohr BR Outcome of very low birth weight infants with histopathologic chorioamnionitis. Obstet Gynecol. 2000;96(2):172-177.

    Not in our library10.1016/s0029-7844(00)00886-3

  45. 45.

    Ecevit A, Anuk-İnce D, Yapakçı E, Association of respiratory distress syndrome and perinatal hypoxia with histologic chorioamnionitis in preterm infants. Turk J Pediatr. 2014;56(1):56-61.

    Not in our library

  46. 46.

    Erdemir G, Kultursay N, Calkavur S, Histological chorioamnionitis: effects on premature delivery and neonatal prognosis. Pediatr Neonatol. 2013;54(4):267-274

    Not in our library10.1016/j.pedneo.2013.03.012

  47. 47.

    Fung G, Bawden K, Chow P, Yu V Long-term outcome of extremely preterm infants following chorioamnionitis. HK J Paediatr. 2003;8(2):87-92.

    Not in our library

  48. 48.

    Gagliardi L, Rusconi F, Bellù R, Zanini R; Italian Neonatal Network Association of maternal hypertension and chorioamnionitis with preterm outcomes. Pediatrics. 2014;134(1):e154-e161

    Not in our library10.1542/peds.2013-3898

  49. 49.

    García-Muñoz Rodrigo F, Galán Henríquez G, Figueras Aloy J, García-Alix Pérez A Outcomes of very-low-birth-weight infants exposed to maternal clinical chorioamnionitis: a multicentre study. Neonatology. 2014;106(3):229-234

    Not in our library10.1159/000363127

  50. 50.

    González-Luis G, Jordán García I, Rodríguez-Miguélez J, Botet Mussons F, Figueras Aloy J Neonatal morbidity and mortality in very low birth weight infants according to exposure to chorioamnionitis [in Spanish]. An Esp Pediatr. 2002;56(6):551-555.

    Not in our library

  51. 51.

    Gray PH, Hurley TM, Rogers YM, Survival and neonatal and neurodevelopmental outcome of 24-29 week gestation infants according to primary cause of preterm delivery. Aust N Z J Obstet Gynaecol. 1997;37(2):161-168

    Not in our library10.1111/j.1479-828x.1997.tb02245.x

  52. 52.

    Hendson L, Russell L, Robertson CM, Neonatal and neurodevelopmental outcomes of very low birth weight infants with histologic chorioamnionitis. J Pediatr. 2011;158(3):397-402

    Not in our library10.1016/j.jpeds.2010.09.010

  53. 53.

    Hitti J, Tarczy-Hornoch P, Murphy J, Hillier SL, Aura J, Eschenbach DA Amniotic fluid infection, cytokines, and adverse outcome among infants at 34 weeks’ gestation or less. Obstet Gynecol. 2001;98(6):1080-1088.

    Not in our library10.1016/s0029-7844(01)01567-8

  54. 54.
    Chorioamnionitis and subsequent lung function in preterm infants. · 2013
    Not checked
  55. 55.

    Jónsson B, Rylander M, Faxelius G Ureaplasma urealyticum, erythromycin and respiratory morbidity in high-risk preterm neonates. Acta Paediatr. 1998;87(10):1079-1084

    Not in our library10.1111/j.1651-2227.1998.tb01418.x

  56. 56.

    Kaukola T, Tuimala J, Herva R, Kingsmore S, Hallman M Cord immunoproteins as predictors of respiratory outcome in preterm infants. Am J Obstet Gynecol. 2009;200(1):100.e1-100.e8

    Not in our library10.1016/j.ajog.2008.07.070

  57. 57.

    Kim SY, Choi CW, Jung E, Neonatal morbidities associated with histologic chorioamnionitis defined based on the site and extent of inflammation in very low birth weight infants. J Korean Med Sci. 2015;30(10):1476-1482

    Not in our library10.3346/jkms.2015.30.10.1476

  58. 58.

    Kirchner L, Helmer H, Heinze G, Amnionitis with Ureaplasma urealyticum or other microbes leads to increased morbidity and prolonged hospitalization in very low birth weight infants. Eur J Obstet Gynecol Reprod Biol. 2007;134(1):44-50

    Not in our library10.1016/j.ejogrb.2006.09.013

  59. 59.

    Lau J, Magee F, Qiu Z, Houbé J, Von Dadelszen P, Lee SK Chorioamnionitis with a fetal inflammatory response is associated with higher neonatal mortality, morbidity, and resource use than chorioamnionitis displaying a maternal inflammatory response only. Am J Obstet Gynecol. 2005;193(3, pt 1):708-713

    Not in our library10.1016/j.ajog.2005.01.017

  60. 60.

    Lee Y, Kim H-J, Choi S-J, Is there a stepwise increase in neonatal morbidities according to histological stage (or grade) of acute chorioamnionitis and funisitis? effect of gestational age at delivery. J Perinat Med. 2015;43(2):259-267

    Not in our library10.1515/jpm-2014-0035

  61. 61.

    Liu Z, Tang Z, Li J, Yang Y Effects of placental inflammation on neonatal outcome in preterm infants. Pediatr Neonatol. 2014;55(1):35-40

    Not in our library10.1016/j.pedneo.2013.05.007

  62. 62.

    Mehta R, Nanjundaswamy S, Shen-Schwarz S, Petrova A Neonatal morbidity and placental pathology. Indian J Pediatr. 2006;73(1):25-28

    Not in our library10.1007/bf02758255

  63. 63.

    Mestan K, Yu Y, Matoba N, Placental inflammatory response is associated with poor neonatal growth: preterm birth cohort study. Pediatrics. 2010;125(4):e891-e898

    Not in our library10.1542/peds.2009-0313

  64. 64.

    Miralles R, Hodge R, Kotecha S Fetal cortisol response to intrauterine microbial colonisation identified by the polymerase chain reaction and fetal inflammation. Arch Dis Child Fetal Neonatal Ed. 2008;93(1):F51-F54

    Not in our library10.1136/adc.2006.110130

  65. 65.

    Misra R, Shah S, Fowell D, Preterm cord blood CD4+ T cells exhibit increased IL-6 production in chorioamnionitis and decreased CD4+ T cells in bronchopulmonary dysplasia. Hum Immunol. 2015;76(5):329-338

    Not in our library10.1016/j.humimm.2015.03.007

  66. 66.

    Miyazaki K, Furuhashi M, Ishikawa K, Impact of chorioamnionitis on short- and long-term outcomes in very low birth weight preterm infants: the Neonatal Research Network Japan. J Matern Fetal Neonatal Med. 2016;29(2):331-337

    Not in our library10.3109/14767058.2014.1000852

  67. 67.

    Mu SC, Lin CH, Chen YL, Impact on neonatal outcome and anthropometric growth in very low birth weight infants with histological chorioamnionitis. J Formos Med Assoc. 2008;107(4):304-310

    Not in our library10.1016/s0929-6646(08)60091-1

  68. 68.

    Nasef N, Shabaan AE, Schurr P, Effect of clinical and histological chorioamnionitis on the outcome of preterm infants. Am J Perinatol. 2013;30(1):59-68

    Not in our library10.1055/s-0032-1321501

  69. 69.

    Nicaise C, Gire C, Fagianelli P, Neonatal consequences of preterm premature rupture of membrane (PPROM) at 24-34 WG: 118 singleton pregnancies [in French]. J Gynecol Obstet Biol Reprod (Paris). 2002;31(8):747-754.

    Not in our library

  70. 70.

    Nishimaki S, Shima Y, Sato M, Urinary β2-microglobulin in premature infants with chorioamnionitis and chronic lung disease. J Pediatr. 2003;143(1):120-122

    Not in our library10.1016/s0022-3476(03)00249-x

  71. 71.

    Ogunyemi D, Murillo M, Jackson U, Hunter N, Alperson B The relationship between placental histopathology findings and perinatal outcome in preterm infants. J Matern Fetal Neonatal Med. 2003;13(2):102-109

    Not in our library10.1080/jmf.13.2.102.109

  72. 72.

    Oh S-H, Kim J-j, Do H-j, Lee BS, Kim K-S, Kim EA-R Preliminary study on neurodevelopmental outcome and placental pathology among extremely low birth weight infants. Korean J Perinatol. 2015;26(1):67-77

    Not in our library10.14734/kjp.2015.26.1.67

  73. 73.

    Ohyama M, Itani Y, Yamanaka M, Re-evaluation of chorioamnionitis and funisitis with a special reference to subacute chorioamnionitis. Hum Pathol. 2002;33(2):183-190

    Not in our library10.1053/hupa.2002.31291

  74. 74.

    O’Shea TM, Klinepeter KL, Meis PJ, Dillard RG Intrauterine infection and the risk of cerebral palsy in very low-birthweight infants. Paediatr Perinat Epidemiol. 1998;12(1):72-83

    Not in our library10.1111/j.1365-3016.1998.00081.x

  75. 75.

    Pappas A, Kendrick DE, Shankaran S,; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network Chorioamnionitis and early childhood outcomes among extremely low-gestational-age neonates. JAMA Pediatr. 2014;168(2):137-147

    Not in our library10.1001/jamapediatrics.2013.4248

  76. 76.

    Perrone S, Toti P, Toti MS, Perinatal outcome and placental histological characteristics: a single-center study. J Matern Fetal Neonatal Med. 2012;25(suppl 1):110-113

    Not in our library10.3109/14767058.2012.664344

  77. 77.

    Plakkal N, Soraisham AS, Trevenen C, Freiheit EA, Sauve R Histological chorioamnionitis and bronchopulmonary dysplasia: a retrospective cohort study. J Perinatol. 2013;33(6):441-445

    Not in our library10.1038/jp.2012.154

  78. 78.

    Polam S, Koons A, Anwar M, Shen-Schwarz S, Hegyi T Effect of chorioamnionitis on neurodevelopmental outcome in preterm infants. Arch Pediatr Adolesc Med. 2005;159(11):1032-1035

    Not in our library10.1001/archpedi.159.11.1032

  79. 79.

    Prendergast M, May C, Broughton S, Chorioamnionitis, lung function and bronchopulmonary dysplasia in prematurely born infants. Arch Dis Child Fetal Neonatal Ed. 2011;96(4):F270-F274

    Not in our library10.1136/adc.2010.189480

  80. 80.

    Redline RW, Wilson-Costello D, Hack M Placental and other perinatal risk factors for chronic lung disease in very low birth weight infants. Pediatr Res. 2002;52(5):713-719

    Not in our library10.1203/00006450-200211000-00017

  81. 81.

    Richardson BS, Wakim E, daSilva O, Walton J Preterm histologic chorioamnionitis: impact on cord gas and pH values and neonatal outcome. Am J Obstet Gynecol. 2006;195(5):1357-1365

    Not in our library10.1016/j.ajog.2006.03.053

  82. 82.

    Rocha G, Proença E, Quintas C, Rodrigues T, Guimarães H Chorioamnionitis and neonatal morbidity [in Portuguese]. Act Med Port. 2006;19(3):207-212.

    Not in our library

  83. 83.

    Sato M, Nishimaki S, Yokota S, Severity of chorioamnionitis and neonatal outcome. J Obstet Gynaecol Res. 2011;37(10):1313-1319

    Not in our library10.1111/j.1447-0756.2010.01519.x

  84. 84.

    Schlapbach LJ, Ersch J, Adams M, Bernet V, Bucher HU, Latal B Impact of chorioamnionitis and preeclampsia on neurodevelopmental outcome in preterm infants below 32 weeks gestational age. Acta Paediatr. 2010;99(10):1504-1509

    Not in our library10.1111/j.1651-2227.2010.01861.x

  85. 85.

    Seliga-Siwecka JP, Kornacka MK Neonatal outcome of preterm infants born to mothers with abnormal genital tract colonisation and chorioamnionitis: a cohort study. Early Hum Dev. 2013;89(5):271-275

    Not in our library10.1016/j.earlhumdev.2012.10.003

  86. 86.

    Smit AL, Been JV, Zimmermann LJ, Automated auditory brainstem response in preterm newborns with histological chorioamnionitis. J Matern Fetal Neonatal Med. 2015;28(15):1864-1869

    Not in our library10.3109/14767058.2014.971747

  87. 87.

    Soraisham AS, Singhal N, McMillan DD, Sauve RS, Lee SK; Canadian Neonatal Network A multicenter study on the clinical outcome of chorioamnionitis in preterm infants. Am J Obstet Gynecol. 2009;200(4):372.e1-372.e6

    Not in our library10.1016/j.ajog.2008.11.034

  88. 88.

    Soraisham AS, Trevenen C, Wood S, Singhal N, Sauve R Histological chorioamnionitis and neurodevelopmental outcome in preterm infants. J Perinatol. 2013;33(1):70-75

    Not in our library10.1038/jp.2012.49

  89. 89.

    Stepan M, Cobo T, Maly J, Neonatal outcomes in subgroups of women with preterm prelabor rupture of membranes before 34 weeks. J Matern Fetal Neonatal Med. 2016;29(14):2373-2377.

    Not in our library10.3109/14767058.2015.1086329

  90. 90.

    Strunk T, Doherty D, Jacques A, Histologic chorioamnionitis is associated with reduced risk of late-onset sepsis in preterm infants. Pediatrics. 2012;129(1):e134-e141

    Not in our library10.1542/peds.2010-3493

  91. 91.

    Suppiej A, Franzoi M, Vedovato S, Marucco A, Chiarelli S, Zanardo V Neurodevelopmental outcome in preterm histological chorioamnionitis. Early Hum Dev. 2009;85(3):187-189

    Not in our library10.1016/j.earlhumdev.2008.09.410

  92. 92.

    Thomas W, Seidenspinner S, Kramer BW, Airway concentrations of angiopoietin-1 and endostatin in ventilated extremely premature infants are decreased after funisitis and unbalanced with bronchopulmonary dysplasia/death. Pediatr Res. 2009;65(4):468-473

    Not in our library10.1203/pdr.0b013e3181991f35

  93. 93.

    Trevisanuto D, Peruzzetto C, Cavallin F, Fetal placental inflammation is associated with poor neonatal growth of preterm infants: a case-control study. J Matern Fetal Neonatal Med. 2013;26(15):1484-1490

    Not in our library10.3109/14767058.2013.789849

  94. 94.

    Tsiartas P, Kacerovsky M, Musilova I, The association between histological chorioamnionitis, funisitis and neonatal outcome in women with preterm prelabor rupture of membranes. J Matern Fetal Neonatal Med. 2013;26(13):1332-1336

    Not in our library10.3109/14767058.2013.784741

  95. 95.

    van Vliet EO, de Kieviet JF, van der Voorn JP, Been JV, Oosterlaan J, van Elburg RM Placental pathology and long-term neurodevelopment of very preterm infants. Am J Obstet Gynecol. 2012;206(6):489.e1-489.e7

    Not in our library10.1016/j.ajog.2012.03.024

  96. 96.

    Watterberg KL, Gerdes JS, Gifford KL, Lin H-M Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics. 1999;104(6):1258-1263

    Not in our library10.1542/peds.104.6.1258

  97. 97.

    Wirbelauer J, Thomas W, Speer CP Response of leukocytes and nucleated red blood cells in very low-birth weight preterm infants after exposure to intrauterine inflammation. J Matern Fetal Neonatal Med. 2011;24(2):348-353

    Not in our library10.3109/14767058.2010.497568

  98. 98.

    Xie A, Zhang W, Chen M, Related factors and adverse neonatal outcomes in women with preterm premature rupture of membranes complicated by histologic chorioamnionitis. Med Sci Monit. 2015;21:390-395

    Not in our library10.12659/msm.891203

  99. 99.

    Young KC, Del Moral T, Claure N, Vanbuskirk S, Bancalari E The association between early tracheal colonization and bronchopulmonary dysplasia. J Perinatol. 2005;25(6):403-407

    Not in our library10.1038/sj.jp.7211297

  100. 100.

    Zanardo V, Savio V, Giacomin C, Rinaldi A, Marzari F, Chiarelli S Relationship between neonatal leukemoid reaction and bronchopulmonary dysplasia in low-birth-weight infants: a cross-sectional study. Am J Perinatol. 2002;19(7):379-386

    Not in our library10.1055/s-2002-35612

  101. 101.

    Zanardo V, Vedovato S, Suppiej A, Histological inflammatory responses in the placenta and early neonatal brain injury. Pediatr Dev Pathol. 2008;11(5):350-354

    Not in our library10.2350/07-08-0324.1

  102. 102.

    Alshehri MA Are preterm infants at high altitude at greater risk for the development of bronchopulmonary dysplasia? J Trop Pediatr. 2014;60(1):68-73

    Not in our library10.1093/tropej/fmt079

  103. 103.

    Ameenudeen SA, Boo NY, Chan LG Risk factors associated with chronic lung disease in Malaysian very low birthweight infants. Med J Malaysia. 2007;62(1):40-45.

    Not in our library

  104. 104.

    Bagchi A, Viscardi RM, Taciak V, Ensor JE, McCrea KA, Hasday JD Increased activity of interleukin-6 but not tumor necrosis factor-α in lung lavage of premature infants is associated with the development of bronchopulmonary dysplasia. Pediatr Res. 1994;36(2):244-252

    Not in our library10.1203/00006450-199408000-00017

  105. 105.

    Baier RJ, Loggins J, Kruger TE Interleukin-4 and 13 concentrations in infants at risk to develop bronchopulmonary dysplasia. BMC Pediatr. 2003;3(1):8

    Not in our library10.1186/1471-2431-3-8

  106. 106.

    Baker CD, Balasubramaniam V, Mourani PM, Cord blood angiogenic progenitor cells are decreased in bronchopulmonary dysplasia. Eur Respir J. 2012;40(6):1516-1522

    Not in our library10.1183/09031936.00017312

  107. 107.

    Bose C, Laughon M, Allred EN,; Elgan Study Investigators Blood protein concentrations in the first two postnatal weeks that predict bronchopulmonary dysplasia among infants born before the 28th week of gestation. Pediatr Res. 2011;69(4):347-353

    Not in our library10.1203/pdr.0b013e31820a58f3

  108. 108.

    Brener Dik PH, Niño Gualdron YM, Galletti MF, Cribioli CM, Mariani GL Bronchopulmonary dysplasia: incidence and risk factors [in Spanish]. Arch Argent Pediatr. 2017;115(5):476-482.

    Not in our library10.5546/aap.2017.eng.476

  109. 109.

    Cederqvist K, Haglund C, Heikkilä P, Pulmonary trypsin-2 in the development of bronchopulmonary dysplasia in preterm infants. Pediatrics. 2003;112(3, pt 1):570-577

    Not in our library10.1542/peds.112.3.570

  110. 110.

    Choi CW, Kim BI, Park JD, Koh YY, Choi JH, Choi JY Risk factors for the different types of chronic lung diseases of prematurity according to the preceding respiratory distress syndrome. Pediatr Int. 2005;47(4):417-423

    Not in our library10.1111/j.1442-200x.2005.02081.x

  111. 111.

    Colaizy TT, Morris CD, Lapidus J, Sklar RS, Pillers D-AM Detection of ureaplasma DNA in endotracheal samples is associated with bronchopulmonary dysplasia after adjustment for multiple risk factors. Pediatr Res. 2007;61(5, pt 1):578-583

    Not in our library10.1203/pdr.0b013e318045be03

  112. 112.

    de Felice C, Latini G, Parrini S, Oral mucosal microvascular abnormalities: an early marker of bronchopulmonary dysplasia. Pediatr Res. 2004;56(6):927-931

    Not in our library10.1203/01.pdr.0000145259.85418.1d

  113. 113.

    Demirel N, Bas AY, Zenciroglu A Bronchopulmonary dysplasia in very low birth weight infants. Indian J Pediatr. 2009;76(7):695-698

    Not in our library10.1007/s12098-009-0110-5

  114. 114.

    Fujioka K, Shibata A, Yokota T, Association of a vascular endothelial growth factor polymorphism with the development of bronchopulmonary dysplasia in Japanese premature newborns. Sci Rep. 2014;4:4459

    Not in our library10.1038/srep04459

  115. 115.

    Fukunaga S, Ichiyama T, Maeba S, MMP-9 and TIMP-1 in the cord blood of premature infants developing BPD. Pediatr Pulmonol. 2009;44(3):267-272

    Not in our library10.1002/ppul.20993

  116. 116.

    Gantar IŠ, Babnik J, Cerar LK, Šinkovec J, Wraber B Prenatal and postnatal risk factors for developing bronchopulmonary dysplasia. Signa Vitae. 2011;6(2):46-51

    Not in our library10.22514/sv62.102011.6

  117. 117.

    Ghezzi F, Gomez R, Romero R, Elevated interleukin-8 concentrations in amniotic fluid of mothers whose neonates subsequently develop bronchopulmonary dysplasia. Eur J Obstet Gynecol Reprod Biol. 1998;78(1):5-10

    Not in our library10.1016/s0301-2115(97)00236-4

  118. 118.

    EXPRESS Group Incidence of and risk factors for neonatal morbidity after active perinatal care: extremely preterm infants study in Sweden (EXPRESS). Acta Paediatr. 2010;99(7):978-992

    Not in our library10.1111/j.1651-2227.2010.01846.x

  119. 119.

    Guimarães H, Rocha G, Vasconcellos G, Risk factors for bronchopulmonary dysplasia in five Portuguese neonatal intensive care units. Rev Port Pneumol. 2010;16(3):419-430

    Not in our library10.1016/s0873-2159(15)30039-8

  120. 120.

    Guo MM-H, Chung C-H, Chen F-S, Chen C-C, Huang H-C, Chung M-Y Severe bronchopulmonary dysplasia is associated with higher fluid intake in very low-birth-weight infants: a retrospective study. Am J Perinatol. 2015;30(2):155-162

    Not in our library10.1055/s-0034-1376393

  121. 121.

    Hansen AR, Barnés CM, Folkman J, McElrath TF Maternal preeclampsia predicts the development of bronchopulmonary dysplasia. J Pediatr. 2010;156(4):532-536

    Not in our library10.1016/j.jpeds.2009.10.018

  122. 122.

    Hikino S, Ohga S, Kinjo T, Tracheal aspirate gene expression in preterm newborns and development of bronchopulmonary dysplasia. Pediatr Int. 2012;54(2):208-214

    Not in our library10.1111/j.1442-200x.2011.03510.x

  123. 123.

    Hyödynmaa E, Korhonen P, Ahonen S, Luukkaala T, Tammela O Frequency and clinical correlates of radiographic patterns of bronchopulmonary dysplasia in very low birth weight infants by term age. Eur J Pediatr. 2012;171(1):95-102

    Not in our library10.1007/s00431-011-1486-6

  124. 124.

    Ikeda S, Kihira K, Yokoi A, Tamakoshi K, Miyazaki K, Furuhashi M The levels of the neutrophil elastase in the amniotic fluid of pregnant women whose infants develop bronchopulmonary dysplasia. J Matern Fetal Neonatal Med. 2015;28(4):479-483

    Not in our library10.3109/14767058.2014.921674

  125. 125.

    Iwatani S, Mizobuchi M, Tanaka S, Increased volume of tracheal aspirate fluid predicts the development of bronchopulmonary dysplasia. Early Hum Dev. 2013;89(2):113-117

    Not in our library10.1016/j.earlhumdev.2012.08.007

  126. 126.

    Kalra VK, Aggarwal S, Arora P, Natarajan G B-type natriuretic peptide levels in preterm neonates with bronchopulmonary dysplasia: a marker of severity? Pediatr Pulmonol. 2014;49(11):1106-1111

    Not in our library10.1002/ppul.22942

  127. 127.

    Kandasamy J, Roane C, Szalai A, Ambalavanan N Serum eotaxin-1 is increased in extremely-low-birth-weight infants with bronchopulmonary dysplasia or death. Pediatr Res. 2015;78(5):498-504

    Not in our library10.1038/pr.2015.152

  128. 128.

    Karagianni P, Rallis D, Fidani L, Glutathion-S-transferase P1 polymorphisms association with broncopulmonary dysplasia in preterm infants. Hippokratia. 2013;17(4):363-367.

    Not in our library

  129. 129.

    Karagianni P, Tsakalidis C, Kyriakidou M, Neuromotor outcomes in infants with bronchopulmonary dysplasia. Pediatr Neurol. 2011;44(1):40-46

    Not in our library10.1016/j.pediatrneurol.2010.07.008

  130. 130.

    Kazzi SNJ, Kim UO, Quasney MW, Buhimschi I Polymorphism of tumor necrosis factor-α and risk and severity of bronchopulmonary dysplasia among very low birth weight infants. Pediatrics. 2004;114(2):e243-e248

    Not in our library10.1542/peds.114.2.e243

  131. 131.

    Akram Khan M, Kuzma-O’Reilly B, Brodsky NL, Bhandari V Site-specific characteristics of infants developing bronchopulmonary dysplasia. J Perinatol. 2006;26(7):428-435

    Not in our library10.1038/sj.jp.7211538

  132. 132.

    Kim D-H, Kim H-S, Shim S-Y, Cord blood KL-6, a specific lung injury marker, correlates with the subsequent development and severity of atypical bronchopulmonary dysplasia. Neonatology. 2008;93(4):223-229

    Not in our library10.1159/000111100

  133. 133.

    Klinger G, Sokolover N, Boyko V, Sirota L, Lerner-Geva L, Reichman B; Israel Neonatal Network Perinatal risk factors for bronchopulmonary dysplasia in a national cohort of very-low-birthweight infants. Am J Obstet Gynecol. 2013;208(2):115.e1-115.e9

    Not in our library10.1016/j.ajog.2012.11.026

  134. 134.

    Koroglu OA, Yalaz M, Levent E, Akisu M, Kültürsay N Cardiovascular consequences of bronchopulmonary dysplasia in prematurely born preschool children. Neonatology. 2013;104(4):283-289

    Not in our library10.1159/000354542

  135. 135.

    Lamboley-Gilmert G, Lacaze-Masmonteil T; Neonatologists of the Curosurf Postmarketing French Study The short-term outcome of a large cohort of very preterm infants treated with poractant alfa (Curosurf) for respiratory distress syndrome: a postmarketing phase IV study. Paediatr Drugs. 2003;5(9):639-645

    Not in our library10.2165/00148581-200305090-00006

  136. 136.

    Lapcharoensap W, Gage SC, Kan P, Hospital variation and risk factors for bronchopulmonary dysplasia in a population-based cohort. JAMA Pediatr. 2015;169(2):e143676

    Not in our library10.1001/jamapediatrics.2014.3676

  137. 137.

    Lardón-Fernández M, Uberos J, Molina-Oya M, Narbona-López E Epidemiological factors involved in the development of bronchopulmonary dysplasia in very low birth-weight preterm infants. Minerva Pediatr. 2017;69(1):42-49.

    Not in our library10.23736/s0026-4946.16.04215-8

  138. 138.

    Leroy S, Caumette E, Waddington C, Hébert A, Brant R, Lavoie PM A time-based analysis of inflammation in infants at risk of bronchopulmonary dysplasia. J Pediatr. 2018;192:60-65.e1

    Not in our library10.1016/j.jpeds.2017.09.011

  139. 139.

    Li Y, Cui Y, Wang C, Liu X, Han J A risk factor analysis on disease severity in 47 premature infants with bronchopulmonary dysplasia. Intractable Rare Dis Res. 2015;4(2):82-86

    Not in our library10.5582/irdr.2015.01000

  140. 140.

    Lin H-C, Su B-H, Chang J-S, Hsu C-M, Tsai C-H, Tsai F-J Nonassociation of interleukin 4 intron 3 and 590 promoter polymorphisms with bronchopulmonary dysplasia for ventilated preterm infants. Biol Neonate. 2005;87(3):181-186

    Not in our library10.1159/000082937

  141. 141.

    Lodha A, Sauvé R, Bhandari V, Need for supplemental oxygen at discharge in infants with bronchopulmonary dysplasia is not associated with worse neurodevelopmental outcomes at 3 years corrected age. PLoS One. 2014;9(3):e90843

    Not in our library10.1371/journal.pone.0090843

  142. 142.

    Lohmann P, Luna RA, Hollister EB, The airway microbiome of intubated premature infants: characteristics and changes that predict the development of bronchopulmonary dysplasia. Pediatr Res. 2014;76(3):294-301

    Not in our library10.1038/pr.2014.85

  143. 143.

    Mahlman M, Karjalainen MK, Huusko JM, Genome-wide association study of bronchopulmonary dysplasia: a potential role for variants near the CRP gene. Sci Rep. 2017;7(1):9271

    Not in our library10.1038/s41598-017-08977-w

  144. 144.

    Mailaparambil B, Krueger M, Heizmann U, Schlegel K, Heinze J, Heinzmann A Genetic and epidemiological risk factors in the development of bronchopulmonary dysplasia. Dis Markers. 2010;29(1):1-9

    Not in our library10.1155/2010/925940

  145. 145.

    May C, Patel S, Kennedy C, Prediction of bronchopulmonary dysplasia. Arch Dis Child Fetal Neonatal Ed. 2011;96(6):F410-F416

    Not in our library10.1136/adc.2010.189597

  146. 146.

    McGowan EC, Kostadinov S, McLean K, Placental IL-10 dysregulation and association with bronchopulmonary dysplasia risk. Pediatr Res. 2009;66(4):455-460

    Not in our library10.1203/pdr.0b013e3181b3b0fa

  147. 147.

    Mittendorf R, Covert R, Montag AG, Special relationships between fetal inflammatory response syndrome and bronchopulmonary dysplasia in neonates. J Perinat Med. 2005;33(5):428-434

    Not in our library10.1515/jpm.2005.076

  148. 148.

    Morrow LA, Wagner BD, Ingram DA, Antenatal determinants of bronchopulmonary dysplasia and late respiratory disease in preterm infants. Am J Respir Crit Care Med. 2017;196(3):364-374

    Not in our library10.1164/rccm.201612-2414oc

  149. 149.

    Novitsky A, Tuttle D, Locke RG, Saiman L, Mackley A, Paul DA Prolonged early antibiotic use and bronchopulmonary dysplasia in very low birth weight infants. Am J Perinatol. 2015;32(1):43-48

    Not in our library10.1055/s-0034-1373844

  150. 150.

    Rindfleisch MS, Hasday JD, Taciak V, Broderick K, Viscardi RM Potential role of interleukin-1 in the development of bronchopulmonary dysplasia. J Interferon Cytokine Res. 1996;16(5):365-373

    Not in our library10.1089/jir.1996.16.365

  151. 151.

    Rocha G, Ribeiro O, Guimarães H Fluid and electrolyte balance during the first week of life and risk of bronchopulmonary dysplasia in the preterm neonate. Clinics (Sao Paulo). 2010;65(7):663-674

    Not in our library10.1590/s1807-59322010000700004

  152. 152.

    Rojas MX, Rojas MA, Lozano JM, Rondón MA, Charry LP Regional variation on rates of bronchopulmonary dysplasia and associated risk factors. ISRN Pediatr. 2012;2012:685151

    Not in our library10.5402/2012/685151

  153. 153.

    Sampath V, Garland JS, Helbling D, Antioxidant response genes sequence variants and BPD susceptibility in VLBW infants. Pediatr Res. 2015;77(3):477-483

    Not in our library10.1038/pr.2014.200

  154. 154.

    Schena F, Francescato G, Cappelleri A, Association between hemodynamically significant patent ductus arteriosus and bronchopulmonary dysplasia. J Pediatr. 2015;166(6):1488-1492

    Not in our library10.1016/j.jpeds.2015.03.012

  155. 155.

    Serenius F, Ewald U, Farooqi A, Holmgren PA, Håkansson S, Sedin G Short-term outcome after active perinatal management at 23-25 weeks of gestation: a study from two Swedish perinatal centres, part 3: neonatal morbidity. Acta Paediatr. 2004;93(8):1090-1097

    Not in our library10.1111/j.1651-2227.2004.tb02722.x

  156. 156.

    Shima Y, Nishimaki S, Nakajima M, Kumasaka S, Migita M Urinary β-2-microglobulin as an alternative marker for fetal inflammatory response and development of bronchopulmonary dysplasia in premature infants. J Perinatol. 2011;31(5):330-334

    Not in our library10.1038/jp.2010.129

  157. 157.

    Soliman N, Chaput K, Alshaikh B, Yusuf K Preeclampsia and the risk of bronchopulmonary dysplasia in preterm infants less than 32 weeks’ gestation. Am J Perinatol. 2017;34(6):585-592

    Not in our library10.1055/s-0036-1594017

  158. 158.

    Stichel H, Bäckström E, Hafström O, Nilsson S, Lappalainen U, Bry K Inflammatory cytokines in gastric fluid at birth and the development of bronchopulmonary dysplasia. Acta Paediatr. 2011;100(9):1206-1212

    Not in our library10.1111/j.1651-2227.2011.02286.x

  159. 159.

    Streubel AH, Donohue PK, Aucott SW The epidemiology of atypical chronic lung disease in extremely low birth weight infants. J Perinatol. 2008;28(2):141-148

    Not in our library10.1038/sj.jp.7211894

  160. 160.

    Tokuriki S, Okuno T, Ohta G, Ohshima Y Carboxyhemoglobin formation in preterm infants is related to the subsequent development of bronchopulmonary dysplasia. Dis Markers. 2015;2015:620921

    Not in our library10.1155/2015/620921

  161. 161.

    Viscardi RM, Muhumuza CK, Rodriguez A, Inflammatory markers in intrauterine and fetal blood and cerebrospinal fluid compartments are associated with adverse pulmonary and neurologic outcomes in preterm infants. Pediatr Res. 2004;55(6):1009-1017

    Not in our library10.1203/01.pdr.0000127015.60185.8a

  162. 162.

    Wang K, Huang X, Lu H, Zhang Z A comparison of KL-6 and Clara cell protein as markers for predicting bronchopulmonary dysplasia in preterm infants. Dis Markers. 2014;2014:736536

    Not in our library10.1155/2014/736536

  163. 163.

    Watterberg KL, Gerdes JS, Cole CH, Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics. 2004;114(6):1649-1657

    Not in our library10.1542/peds.2004-1159

  164. 164.

    Choi CW, Kim BI, Kim HS, Park JD, Choi JH, Son DW Increase of interleukin-6 in tracheal aspirate at birth: a predictor of subsequent bronchopulmonary dysplasia in preterm infants. Acta Paediatr. 2006;95(1):38-43

    Not in our library10.1080/08035250500404085

  165. 165.

    Xie L, Chee YY, Wong KY, Cheung YF Cardiac mechanics in children with bronchopulmonary dysplasia. Neonatology. 2016;109(1):44-51

    Not in our library10.1159/000441051

  166. 166.

    Yoon BH, Romero R, Kim KS, A systemic fetal inflammatory response and the development of bronchopulmonary dysplasia. Am J Obstet Gynecol. 1999;181(4):773-779

    Not in our library10.1016/s0002-9378(99)70299-1

  167. 167.

    Zhang H, Fang J, Su H, Chen M Risk factors for bronchopulmonary dysplasia in neonates born at ≤1500 g (1999-2009). Pediatr Int. 2011;53(6):915-920

    Not in our library10.1111/j.1442-200x.2011.03399.x

  168. 168.

    Curley AE, Sweet DG, Thornton CM, Chorioamnionitis and increased neonatal lung lavage fluid matrix metalloproteinase-9 levels: implications for antenatal origins of chronic lung disease. Am J Obstet Gynecol. 2003;188(4):871-875

    Not in our library10.1067/mob.2003.215

  169. 169.

    Durrmeyer X, Kayem G, Sinico M, Dassieu G, Danan C, Decobert F Perinatal risk factors for bronchopulmonary dysplasia in extremely low gestational age infants: a pregnancy disorder-based approach. J Pediatr. 2012;160(4):578-583.e2

    Not in our library10.1016/j.jpeds.2011.09.025

  170. 170.

    Eriksson L, Haglund B, Odlind V, Altman M, Kieler H Prenatal inflammatory risk factors for development of bronchopulmonary dysplasia. Pediatr Pulmonol. 2014;49(7):665-672

    Not in our library10.1002/ppul.22881

  171. 171.

    Honma Y, Yada Y, Takahashi N, Momoi MY, Nakamura Y Certain type of chronic lung disease of newborns is associated with Ureaplasma urealyticum infection in utero. Pediatr Int. 2007;49(4):479-484

    Not in our library10.1111/j.1442-200x.2007.02391.x

  172. 172.

    Kent A, Dahlstrom JE Chorioamnionitis/funisitis and the development of bronchopulmonary dysplasia. J Paediatr Child Health. 2004;40(7):356-359

    Not in our library10.1111/j.1440-1754.2004.00366.x

  173. 173.

    Kewitz G, Wudel S, Hopp H, Hopfenmüller W, Vogel M, Roots I Below median birth weight in appropriate-for-gestational-age preterm infants as a risk factor for bronchopulmonary dysplasia. J Perinat Med. 2008;36(4):359-364

    Not in our library10.1515/jpm.2008.056

  174. 174.

    Kim BI, Choi CW, Park JD, Kim CJ, Choi JH The effect of histologic chorioamnionitis on the development of respiratory distress syndrome and chronic lung disease in preterm infants. Korean J Pediatr. 2004;47(2):150-156.

    Not in our library

  175. 175.

    Lahra MM, Beeby PJ, Jeffery HE Intrauterine inflammation, neonatal sepsis, and chronic lung disease: a 13-year hospital cohort study. Pediatrics. 2009;123(5):1314-1319

    Not in our library10.1542/peds.2008-0656

  176. 176.

    Lee HJ, Kim E-K, Kim H-S, Choi CW, Kim BI, Choi J-H Chorioamnionitis, respiratory distress syndrome and bronchopulmonary dysplasia in extremely low birth weight infants. J Perinatol. 2011;31(3):166-170

    Not in our library10.1038/jp.2010.113

  177. 177.

    Metcalfe A, Lisonkova S, Sabr Y, Stritzke A, Joseph KS Neonatal respiratory morbidity following exposure to chorioamnionitis. BMC Pediatr. 2017;17(1):128

    Not in our library10.1186/s12887-017-0878-9

  178. 178.

    Paananen R, Husa A-K, Vuolteenaho R, Herva R, Kaukola T, Hallman M Blood cytokines during the perinatal period in very preterm infants: relationship of inflammatory response and bronchopulmonary dysplasia. J Pediatr. 2009;154(1):39-43.e3

    Not in our library10.1016/j.jpeds.2008.07.012

  179. 179.

    Rocha G, Proença E, Areias A, HLA and bronchopulmonary dysplasia susceptibility: a pilot study. Dis Markers. 2011;31(4):199-203

    Not in our library10.1155/2011/236082

  180. 180.

    Shima Y, Kumasaka S, Migita M Perinatal risk factors for adverse long-term pulmonary outcome in premature infants: comparison of different definitions of bronchopulmonary dysplasia/chronic lung disease. Pediatr Int. 2013;55(5):578-581

    Not in our library10.1111/ped.12151

  181. 181.

    Štimac M, Juretić E, Vukelić V, Matasić NP, Kos M, Babić D Effect of chorioamnionitis on mortality, early onset neonatal sepsis and bronchopulmonary dysplasia in preterm neonates with birth weight of <1,500 grams. Coll Antropol. 2014;38(1):167-171.

    Not in our library

  182. 182.

    Torchin H, Lorthe E, Goffinet F, Histologic chorioamnionitis and bronchopulmonary dysplasia in preterm infants: the epidemiologic study on low gestational ages 2 cohort. J Pediatr. 2017;187:98-104.e3

    Not in our library10.1016/j.jpeds.2017.05.019

  183. 183.

    Natarajan G, Glibetic M, Thomas RL, Aranda JV Chorioamnionitis and ontogeny of circulating prostaglandin and thromboxane in preterm infants. Am J Perinatol. 2008;25(8):491-497

    Not in our library10.1055/s-0028-1085068

  184. 184.
    Chorioamnionitis Is a Risk Factor for Intraventricular Hemorrhage in Preterm Infants: A Systematic Review and Meta-Analysis · 2018
    Not checked
  185. 185.

    Villamor-Martinez E, Cavallaro G, Raffaeli G, Chorioamnionitis as a risk factor for retinopathy of prematurity: an updated systematic review and meta-analysis. PLoS One. 2018;13(10):e0205838

    Not in our library10.1371/journal.pone.0205838

  186. 186.

    Villamor-Martínez E, Pierro M, Cavallaro G, Mosca F, Kramer B, Villamor E Probiotic supplementation in preterm infants does not affect the risk of bronchopulmonary dysplasia: a meta-analysis of randomized controlled trials. Nutrients. 2017;9(11):E1197

    Not in our library10.3390/nu9111197

  187. 187.

    Jobe AH, Bancalari EH Controversies about the definition of bronchopulmonary dysplasia at 50 years. Acta Paediatr. 2017;106(5):692-693

    Not in our library10.1111/apa.13775

  188. 188.

    Poindexter BB, Feng R, Schmidt B,; Prematurity and Respiratory Outcomes Program Comparisons and limitations of current definitions of bronchopulmonary dysplasia for the prematurity and respiratory outcomes program. Ann Am Thorac Soc. 2015;12(12):1822-1830

    Not in our library10.1513/annalsats.201504-218oc

  189. 189.

    Beam KS, Aliaga S, Ahlfeld SK, Cohen-Wolkowiez M, Smith PB, Laughon MM A systematic review of randomized controlled trials for the prevention of bronchopulmonary dysplasia in infants. J Perinatol. 2014;34(9):705-710

    Not in our library10.1038/jp.2014.126

  190. 190.

    Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics. 1988;82(4):527-532.

    Not in our library

  191. 191.

    Walsh MC, Wilson-Costello D, Zadell A, Newman N, Fanaroff A Safety, reliability, and validity of a physiologic definition of bronchopulmonary dysplasia. J Perinatol. 2003;23(6):451-456

    Not in our library10.1038/sj.jp.7210963

  192. 192.

    McElrath TF, Hecht JL, Dammann O,; ELGAN Study Investigators Pregnancy disorders that lead to delivery before the 28th week of gestation: an epidemiologic approach to classification. Am J Epidemiol. 2008;168(9):980-989

    Not in our library10.1093/aje/kwn202

  193. 193.

    Jobe AH, Kallapur SG Chorioamnionitis, surfactant, and lung disease in very low birth weight infants. J Pediatr. 2010;156(1):3-4

    Not in our library10.1016/j.jpeds.2009.08.009

  194. 194.

    Revello R, Alcaide MJ, Dudzik D, Abehsera D, Bartha JL Differential amniotic fluid cytokine profile in women with chorioamnionitis with and without funisitis. J Matern Fetal Neonatal Med. 2016;29(13):2161-2165.

    Not in our library10.3109/14767058.2015.1077512

  195. 195.

    Gantert M, Been JV, Gavilanes AW, Garnier Y, Zimmermann LJ, Kramer BW Chorioamnionitis: a multiorgan disease of the fetus? J Perinatol. 2010;30(suppl):S21-S30

    Not in our library10.1038/jp.2010.96

  196. 196.

    Bax L, Moons KG Beyond publication bias. J Clin Epidemiol. 2011;64(5):459-462

    Not in our library10.1016/j.jclinepi.2010.09.003

  197. 197.

    Jin ZC, Zhou XH, He J Statistical methods for dealing with publication bias in meta-analysis. Stat Med. 2015;34(2):343-360

    Not in our library10.1002/sim.6342

  198. 198.

    Higgins RD, Saade G, Polin RA,; Chorioamnionitis Workshop Participants Evaluation and management of women and newborns with a maternal diagnosis of chorioamnionitis: summary of a workshop. Obstet Gynecol. 2016;127(3):426-436

    Not in our library10.1097/aog.0000000000001246

  199. 199.

    Thompson SG, Higgins JP How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002;21(11):1559-1573

    Not in our library10.1002/sim.1187

Cited by papers we hold 3

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.